Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner

Molecular Cancer Therapeutics

Volumn 12, Issue 4, 2013, Pages 352-360

  McCarthy, Anna R ^a   Sachweh, Marijke C C ^a   Higgins, Maureen ^b   Campbell, Johanna ^b   Drummond, Catherine J ^a   Van Leeuwen, Ingeborg M M ^a   Pirrie, Lisa ^c   Ladds, Marcus J G W ^a   Westwood, Nicholas J ^c   Laín, Sonia ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; PROTEIN P53; SIRTUIN 2; TENOVIN 6; TENOVIN D3; TRANSCRIPTION FACTOR; TRICHOSTATIN A; TUBACIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ANILIDES; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; SIRTUIN 2; THIOUREA; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84876473075     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0900     Document Type: Article

References (30)

1. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009;10:32-42.
2. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-9.
3. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008;26: 795-7. (Pubitemid 351961456)
4. Feng B, Ng JH, Heng JC, Ng HH. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009;4:301-12.
5. McCarthy AR, Hollick JJ, Westwood NJ. The discovery of nongeno-toxic activators of p53: building on a cell-based high-throughput screen. Semin Cancer Biol 2010;20:40-5.
6. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008;13:454-63. (Pubitemid 351609441)
7. Staples OD, Hollick JJ, Campbell J, Higgins M, McCarthy AR, Appleyard V, et al. Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen. Cell Cycle 2008;7:3417-27.
8. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107:137-48. (Pubitemid 33035941)
9. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-59. (Pubitemid 33035942)
10. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD-dependent tubulin deacetylase. Mol Cell 2003;11:437-44. (Pubitemid 36293837)
11. Li L, Wang LS, Li L, Wang ZQ, Ho YW, McDonald T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012;21: 266-81.
12. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, et al. SIRT1 promotes N-Myc oncogenesis througha positivefeedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 2011;7:e1002135.
13. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Luscher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA 2012;109:E187-E96.
14. Yuan HF, Wang ZQ, Li L, Zhang H, Modi H, Horne D, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012;119:1904-14.
15. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007;39:1367-74. (Pubitemid 47031035)
16. Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzyn-kiewicz Z, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002;1:937-41.
17. McCarthy AR, Pirrie L, Hollick JJ, Ronseaux S, Campbell J, Higgins M, et al. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg Med Chem 2012;20:1779-93.
18. van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2011;10:1590-8.
19. Berkson RG, Hollick JJ, Westwood NJ, Woods JA, Lane DP, Lain S. Pilot screening programme for small molecule activators of p53. Int J Cancer 2005;115:701-10. (Pubitemid 40776692)
20. Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009;74:619-24.
21. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010;285:8340-51.
22. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-94. (Pubitemid 36457739)
23. Gerlitz G, Bustin M. Efficient cell migration requires global chromatin condensation. J Cell Sci 2010;123:2207-17.
24. van Leeuwen I, Lain S. Sirtuins and p53. Adv Cancer Res 2009; 102:171-95.
25. Schreiber SL. The small-molecule approach to biology. Chem Eng News 2003;81:51-61.
26. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010;31: 605-17.
27. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007;317:516-9. (Pubitemid 47196116)
28. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci U S A 2010;107:7927-32.
29. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000;97:10014-9.
30. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8. (Pubitemid 38174664)